Granules India (GRANULES.NS)

Executive Summary

Granules India is a vertically integrated pharmaceutical manufacturer based in Hyderabad, India, with a focus on active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The company's integrated model provides cost advantages and supply chain reliability, serving a global customer base with key products including Paracetamol, Ibuprofen, Metformin, and Guaifenesin. Granules operates several US FDA-approved facilities and has a strong pipeline of abbreviated new drug applications (ANDAs). The company's strategy emphasizes operational efficiency, scale, and diversification within the generic space. Financially, Granules India has demonstrated consistent revenue growth and profitability, driven by its strong position in the US generics market and expanding presence in regulated markets. However, the company faces risks from pricing pressure in generics and regulatory compliance costs. Overall, Granules India is well-positioned to benefit from the growing demand for affordable generics globally.

Upcoming Catalysts (preview)

• Q2 2026US FDA approvals for new ANDAs, including high-value generics65% success
• Q1 2026Completion of capacity expansion at API and formulation facilities80% success
• Q3 2026Strategic partnership or licensing deal for complex generics50% success